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mAcute graft-versus-host disease (GVHD) is one of
he major hazards in allogeneic hematopoietic stem
ell transplantation (ASCT) [1-3]. This syndrome was
etected in experimental animals and was called sec-
ndary disease or runt disease. Allogeneic, in contrast to
yngeneic, animals developed fetal diarrhea and skin
esions after total body irradiation and marrow trans-
lantation. Other symptoms included hypoplasia of
he lymphatic system, diarrhea, necrosis of liver cells,
nd growth retardation. The main effector cells of
VHD are thought to be cytotoxic T cells. However,
cute GVHD may occur in the absence of detectable
ytotoxic T cells. In experimental animals and also in
umans, it is well established that the removal of T
ells from the donated marrow may completely pre-
ent acute GVHD. Disparity for the various loci of
he HLA system is of utmost importance for the de-
elopment of GVHD. However, in humans, acute
VHD occurs despite a suitable HLA-identical sib-
ing donor. Recipients of ASCT from HLA-compat-
ble, unrelated donors experience more GVHD than
hose from HLA-identical siblings.
The main target organs for acute GVHD in hu-
ans are skin, gut, and liver [1-4]. Generally acute
VHD appears during the ﬁrst 3 months after trans-
lantation, but it may also appear later. Acute GVHD
s graded on a 5-point scale from 0 to IV [4,5]. GVHD
s absent at grade 0; at grade I, mild GVHD is a local
kin rash, which in some instances may disappear
ithout therapy; grade II, or moderate, GVHD can be
skin rash alone affecting most of the body or a skin
ash in association with gut or liver symptoms; grade
II, or severe, GVHD involves skin, gut, and liver; and
rade IV is life-threatening (Figure 1). Skin GVHD
ften presents as a micropapillary skin rash, which
ay start in the palms, soles, or face. In more severe
orms, the entire body may be affected with necrosis in
xtreme cases. When the liver is affected, bilirubin t
B & M Tnd the liver enzymes S-ALAT and S-ASAT are in-
reased. In more severe forms, ascites and liver en-
argement may occur. During gastrointestinal
VHD, the symptoms are diarrhea, abdominal pain,
nd, in severe cases, hemorrhage. Severe immunologic
eﬁciency accompanies GVHD, and infections by
acteria, fungi, and viruses occur frequently and are
ften fatal.
Donor T cells are responsible for triggering GVHD
nd proliferate after activation by recipient antigens,
hich are expressed on host cells in the form of major
istocompatibility complex (MHC) class I or class II
ntigens, viral antigens, or minor antigenic peptides,
ncluding epithelial cell–associated antigens. Antigen-
resenting cells, such as dendritic cells or macrophages,
resent the antigens to T cells. CD4 (helper) T cells
ecognize antigens in association with HLA class II mol-
cules. Interleukin (IL)–1–produced monocytes and
ther factors, such as epidermal cell–derived thymocyte-
ctivating factor, stimulate the T-helper cells, which in
urn release IL-2; this activates cytotoxic CD8 T cells,
hich react with MHC class I positive targets. In addi-
ion, natural killer cells and macrophages seem to par-
icipate in the development of GVHD. A subset of ac-
ivated CD4 cells also produces interferon , which
nhances the expression of MHC class II on epithelial
ells and macrophages, thus further stimulating T-cell
nd natural killer cell activation. Humoral immune
echanisms may also be involved in GVHD.
HLA disparity between recipient and donor is a
ajor risk factor for acute and chronic GVHD. Other
isk factors associated with acute GVHD include female
onor to male recipient, seropositivity to several herpes-
iruses in the recipient and donor, certain HLA alleles,
nd the host environment [3,6,7]. GVHD may also ap-
ear in a chronic form, which generally appears from 3
onths to after a year after ASCT [8]. The manifesta-ions of chronic GVHD include skin disease, keratocon-
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1unctivitis, generalized sicca syndrome, severe oral mu-
ositis, esophageal and vaginal strictures, malabsorption,
asting, liver disease, pulmonary insufﬁciency, bronchi-
litis obliterans, myositis, neuropathy, and immunodeﬁ-
iency. Chronic GVHD is associated with infections.
nfections with encapsulated gram-positive bacteria are
ommon and may cause septicemia, bronchopneumonia,
nd sinusitis. Chronic GVHD can markedly impair
rowth and development in children. Chronic GVHD
ay be graded as limited, which may be a localized skin
nvolvement or hepatic dysfunction (Table 1) [9]. Exten-
igure 1. Clinical grading of acute GVHD. Reprinted with permi
able 1. Classiﬁcation of Chronic Graft-versus-Host Disease*
ubclinical graft-versus-host disease:
Histologically positive but no clinical symptoms
linical limited chronic graft-versus-host disease:
One or both of
Localized skin involvement
Hepatic dysfunction (due to chronic GVHD)
xtensive chronic graft-versus-host disease:
Either
Generalized skin involvement
or
Localized skin involvement or hepatic dysfunction due to
chronoic GVHD, or both
plus
Liver histology showing chronic aggressive hepatitis,
bridging necrosis, or cirrhosis
or
Involvement of eye (Schirmer’s test with less than 5 mm
wetting) or
Involvement of minor salivary glands or oral mucosa
demonstrated on labial biopsy
or
Involvement of any other target organ (lung, kidney)dReprinted with permission.9
8ive chronic GVHD includes generalized skin involve-
ent or involvement of other organs. Chronic GVHD
ay also be classiﬁed as mild, moderate, or severe, ac-
ording to the judgment of the treating physician [10].
he latter is more correlated with the clinical outcome
han the former deﬁnition of grading. Risk factors for
hronic GVHD include previous acute GVHD, high
ecipient or donor age, treatment with donor buffy-coat
ells, peripheral blood stem cell graft compared with
one marrow graft, an alloimmune female donor for a
ale recipient, chronic myeloid leukemia, and seropos-
tivity for several herpesviruses in the recipient and do-
or.
GVHD may be completely abolished if a T cell–
epleted graft is transplanted [11]. However, in animal
odels and clinically, T-cell depletion is associated with
n increased risk of graft failure and with leukemic re-
apse. Immunosuppression or modulation is necessary to
revent GVHD. Prophylaxis treatment by methotrexate
r cyclosporine used as single agents results in compa-
able incidences of acute and chronic GVHD. When
ombined, these agents result in a dramatic decrease in
cute and chronic GVHD and an improved survival [12].
or the last 2 decades, cyclosporine combined with 4
oses of methotrexate has been the standard prophylac-
ic regimen to prevent GVHD. Cyclosporine may be
eplaced by tacrolimus with comparable outcome. In
ore recent years, methotrexate has been replaced by
ycophenolate mofetil. However, it is controversial
hether this will result in an increased or comparable
ncidence of GVHD compared with methotrexate. A
romising new combination is tacrolimus and rapamy-
in. However, comparative studies are needed to eluci-
5]ate whether this results in reduced incidence of GVHD
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Bnd improved survival compared with cyclosporine com-
ined with methotrexate.
Despite prophylaxis, some patients develop acute
VHD [2,3]. Standard treatment includes high-dose
teroids, and if this treatment fails, other agents may
e tried, the most common being antithymocyte glob-
lin. However, in advanced acute GVHD, outcome is
ismal whether patients are treated with high-dose
teroids or antithymocyte globulin. Other agents that
ave been used to treat acute GVHD include anti–
L-2 antibodies, monoclonal antibodies against the
D3 receptor, anti–tumor necrosis factor  antibody,
ecombinant human IL-1 receptor antibodies, and
apamycin. Currently, no effective therapy exists for
evere steroid-refractory acute GVHD. A new exper-
mental approach is the use of mesenchymal stem
ells, which have immunomodulatory properties and
lso may repair damaged tissue [13].
Chronic GVHD is treated with steroids, alone or
ombined with cyclosporine [3,8]. Other treatments in-
olve thalidomide; psoralen and ultraviolet light; or ex-
racorporeal psoralene and ultraviolet light, total lym-
hoid irradiation, and anti–B-cell antibodies (anti-
D19).
Because of the high mortality associated with
oderate to severe acute GVHD, this complication
as a profound effect on the prognosis after ASCT.
owever, GVHD has an antileukemia effect [14,15].
he graft-versus-leukemia effect is especially pro-
ounced with chronic GVHD. Patients with chronic
VHD have a lower probability of relapse and a
etter leukemia-free survival compared with patients
ithout chronic GVHD. The best leukemia-free sur-
ival seems to be obtained in patients with mild acute
nd mild chronic GVHD. There is also a graft-versus-
eukemia effect in the absence of GVHD. This has
een noted because there is less relapse among pa-
ients undergoing ASCT from HLA-identical sibling
onors, who do not develop any GVHD, compared
ith recipients of syngeneic grafts and also compared
ith patients receiving autografts. However, despite
he potential beneﬁts of an antileukemic effect of
VHD, GVHD is one of the major obstacles to
uccess after ASCT. However, the best leukemia-free
urvival is seen with grade I acute GVHD [16]. A
raft-versus-tumor effect is also seen in patients un-
ergoing ASCT for solid tumors. Such an effect has
een noted in patients with renal cell carcinoma,
reast cancer, and colon carcinoma.
In conclusion, both acute and chronic GVHD
ontinue to be major problems after ASCT. The cur-
ent prophylaxis combining cyclosporine and metho-
rexate has reduced the incidence and severity of acute
nd chronic GVHD and has improved long-term sur-
ival. However, the incidence of acute and chronic
VHD remains high, especially in recipients of HLA-
onidentical and unrelated grafts. The clinical appear- 1
B & M Tnce of GVHD has changed over the years, in part
ecause of better immune prophylaxis and also better
rophylaxis and therapy for infections. Less-toxic reg-
mens, such as nonmyeloablative conditioning, have
een thought to reduce the probability of acute and
hronic GVHD. This has not been the case, which
ay be because older patients who are more likely to
evelop GVHD have undergone ASCT. In patients
ith leukemia and other malignancies, GVHD may be
eeded for an antitumor effect. However, in recipients
ith nonmalignant disorders, the most effective pre-
ention of GVHD should be used. Although progress
as been made, there is room for improved prevention
nd treatment of GVHD.
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